• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Aug 1, 2006; 116(8): 2297–2305.
Published online Jul 20, 2006. doi:  10.1172/JCI27920
PMCID: PMC1513050

Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production


Many respiratory pathogens, including Hemophilus influenzae, Streptococcus pneumoniae, and Pseudomonas aeruginosa, express neuraminidases that can cleave α2,3-linked sialic acids from glycoconjugates. As mucosal surfaces are heavily sialylated, neuraminidases have been thought to modify epithelial cells by exposing potential bacterial receptors. However, in contrast to neuraminidase produced by the influenza virus, a role for bacterial neuraminidase in pathogenesis has not yet been clearly established. We constructed a mutant of P. aeruginosa PAO1 by deleting the PA2794 neuraminidase locus (Δ2794) and tested its virulence and immunostimulatory capabilities in a mouse model of infection. Although fully virulent when introduced i.p., the Δ2794 mutant was unable to establish respiratory infection by i.n. inoculation. The inability to colonize the respiratory tract correlated with diminished production of biofilm, as assessed by scanning electron microscopy and in vitro assays. The importance of neuraminidase in biofilm production was further demonstrated by showing that viral neuraminidase inhibitors in clinical use blocked P. aeruginosa biofilm production in vitro as well. The P. aeruginosa neuraminidase has a key role in the initial stages of pulmonary infection by targeting bacterial glycoconjugates and contributing to the formation of biofilm. Inhibiting bacterial neuraminidases could provide a novel mechanism to prevent bacterial pneumonia.


Neuraminidases (sialidases) are produced by a wide variety of mucosal pathogens, ranging from Streptococcus pneumoniae in the airway to Vibrio cholerae in the gut (1). While the central role of viral neuraminidase in pathogenesis of influenza is well established (2) and provides a target for both vaccines and chemotherapy, the contribution of bacterial neuraminidase to the pathogenesis of infection is not as clearly defined. Neuraminidase-producing species such as Hemophilus (3), S. pneumoniae (4, 5), and Pseudomonas aeruginosa (6) share a common ecological niche, colonizing the heavily sialylated secretions and surfaces of the upper respiratory tract. Although each can bind to asialylated glycolipids exposed by neuraminidase activity (7), they differ substantially in their ability to either metabolize (8) or incorporate sialic acid into surface structures (9). Thus it is likely that bacterial neuraminidases interact with both microbial and eukaryotic glycoconjugates (1).

P. aeruginosa is a major opportunistic pathogen, an important cause of nosocomial pneumonia as well as the chief cause of lung infection in cystic fibrosis (CF). Over 2 decades ago, neuraminidase production in isolates of P. aeruginosa from CF patients was described and suggested to contribute to pulmonary infection (10). In vitro studies documented that many pulmonary pathogens including P. aeruginosa bind to the GalNAcβ1,4Gal moiety exposed on asialylated glycolipids (7), suggesting that the ability to desialylate mucosal surfaces could contribute to bacterial colonization of the airways. The P. aeruginosa neuraminidase was cloned and characterized. It was shown to be osmoregulated, thought to be consistent with expression in the milieu of the CF lung (6) and capable of exposing the receptor asialoganglioside gangliotetraosylceramide (Galβ1,2GalNAcβ1,4Galβ1,4Glcβ1,1Cer) (asialoGM1) on the surface of CF airway cells in vitro, implying a role in pathogenesis (11). However, data confirming P. aeruginosa adherence to the airway surface in CF patients has been lacking (12). The current consensus suggests that organisms are predominantly entrapped in dehydrated secretions of the lung and — by shedding proinflammatory products — activate airway inflammation (13), a model that does not require direct attachment of organisms to the epithelial surface. Nonetheless, analyses of P. aeruginosa gene expression in CF patients document that the PA2794 neuraminidase locus is one of the most highly expressed genes in this patient population in vivo (14). Unlike other respiratory pathogens, P. aeruginosa cannot use sialic acid as a carbon source, nor does it contain sialic acid as a component of its LPS (15). Thus it seemed likely that there was some additional function for the enzyme relevant to the pathogenesis of respiratory tract infection. To better define the importance of bacterial neuraminidases, we constructed a P. aeruginosa mutant lacking the PA2794 nanA locus and analyzed it in a mouse model of infection. Our studies showed that the P. aeruginosa neuraminidase is involved in biofilm formation contributing to initial colonization of the airway. Furthermore, we demonstrated that this activity can be blocked by viral neuraminidase inhibitors in clinical use indicating a novel therapeutic target for preventing baterial pneumonia.


Construction of a nanA null mutant.

Sequence predictions for the PA2794 locus were analyzed using ORFcurator (16), which identified both the sialidase region and a domain expected to have autotransporter function (Figure (Figure1A)1A) (17) consistent with previous reports (18). The predicted sequence included the ASP boxes expected to interact with sialic acid (Figure (Figure1B)1B) (19). An in-frame nonpolar deletion allele of the predicted neuraminidase open reading frame (PA2794, nanA) was constructed and used to replace the wild-type gene in PAO1 (Figure (Figure2A).2A). Loss of neuraminidase activity was documented by an assay monitoring the ability of culture supernatants to expose asialoGM1 from human airway epithelial cells (Figure (Figure2B)2B) (6). The deletion was shown not to impose any metabolic consequences on the fitness of the mutant, as growth curves of the wild-type, mutant, and complemented strains were comparable (Figure (Figure2C). 2C).

Figure 1
Properties of the PA2794 locus.
Figure 2
Characterization of the Δ2794 mutant.

Virulence properties of Δ2794 neuraminidase mutant differ depending upon the route of inoculation.

To evaluate the role of the neuraminidase in respiratory tract infection, 2 × 108 CFU inocula of the wild-type PAO1, Δ2794, and Δ2794 + nanA strains were used to infect 7- to 10-day-old BALB/c mice by the i.n. route, and morbidity and mortality were assessed 18 hours after infection (Figure (Figure3,3, A–D) (20). In contrast to PAO1, the Δ2794 mutant was readily cleared from the respiratory tract: 33% of the mice infected with Δ2794 developed pneumonia versus 78% of the mice infected with PAO1 (P < 0.05). Significantly fewer mice infected with the Δ2794 mutant became bacteremic: 10% versus 44% (P < 0.05). Mortality rates were not significantly different (Figure (Figure3A).3A). Quantification of lung mRNA indicated less chemokine KC expression, which correlated with fewer polymorphonuclear leukocytes (PMNs) recruited to the lungs, in mice inoculated with Δ2794 compared with PAO1 (P < 0.05; Figure Figure3,3, B and C). Histopathology similarly demonstrated substantially decreased inflammation in Δ2794-infected lungs (Figure (Figure3D). 3D).

Figure 3
Comparison of PAO1 and Δ2794 virulence.

We also compared the virulence of wild-type and Δ2794 strains when introduced into mice by the i.p. route. This route of administration could potentially uncover differences in the immunogenicity of the mutant due to changes in glycosylation that might affect LPS or other surface structures. However, there were no differences in virulence when equal inocula of the wild-type and mutant strains were injected by the i.p. route (Figure (Figure3E). 3E).

Immunostimulatory properties of the PA2794 mutant.

To account for the attenuated phenotype of the Δ2794 mutant when introduced into the airways, we characterized its ability to attach to and stimulate chemokine and cytokine expression in both airway epithelial cells and macrophages (Figures (Figures44 and and5).5). Although we had documented that PAO1 culture supernatant exposed more asialoGM1 on the surface of human airway cells than did Δ2794 (Figure (Figure2B),2B), there were no significant differences in either bacterial adherence or the induction of IL-8 expression by the wild-type and Δ2794 mutant strains (Figure (Figure4,4, A and B), in contrast to published reports that used concentrated purified enzyme (6). As bacterial modification of surface glycoconjugates could affect interactions with phagocytic cells, we compared the uptake and killing by RAW cells. Both wild-type and mutant bacteria were efficiently phagocytosed by RAW cells and both induced equivalent amounts of TNF-α production (Figure (Figure5,5, A and B). In addition, we compared outer membrane proteins (OMPs) and secreted exoproducts from the wild-type and mutant strains and detected no differences (data not shown).

Figure 4
Interactions of PAO1 and Δ2794 with human airway epithelial cells.
Figure 5
Interactions of PAO1 and Δ2794 with phagocytic cells.

Effects of the PA2794 neuraminidase locus on LPS.

Having found no biologically important alteration in eukaryotic surface glycosylation that could be attributed to effects of the neuraminidase, we next examined possible effects on surface structures including LPS. An extensive biochemical analysis of P. aeruginosa LPS had previously failed to identify sialic acid (15), in contrast to other neuraminidase-producing organisms such as Hemophilus (21). Although the enzyme could target a different amino sugar involved in LPS biosynthesis, a GC–mass spectroscopic analysis kindly performed by R. Ernst (University of Washington, Seattle, Washington, USA) did not reveal any differences in LPS lipid A structures among the wild-type, mutant, or complemented strains (data not shown) (22). As LPS structure is responsible for the resistance of P. aeruginosa to the lytic affects of normal human complement, we compared PAO1 and Δ2794 sensitivity to 10% human serum and also found no differences (data not shown). These negative results, along with the observation that the wild-type and mutant strains were equally virulent when injected i.p., indicate that the Δ2794 mutation does not have a major effect on LPS or its immunogenicity.

The PA2794 locus affects biofilm formation.

Since the Δ2794 mutant appeared to be deficient solely in its ability to initiate infection by the mucosal route, we postulated that the neuraminidase might target other bacterial exopolysaccharides, such as those involved in biofilm formation. Bacteria-bacteria interactions were examined using crystal violet staining to quantify biofilm production in 96-well plates (Figure (Figure6A)6A) (23). The wild-type strain PAO1 containing an empty vector was used as a control, and all strains were grown under identical conditions in gentamicin selection. The Δ2794 mutant with the empty vector produced significantly less biofilm than PAO1 also containing the control vector (P < 0.001). Biofilm production by the Δ2794 mutant expressing the cloned nanA locus was significantly greater than that of the parental strain (P < 0.0001), consistent with the constitutive expression of the cloned gene. Similarly, overexpression of nanA by expressing the cloned gene in PAO1 also resulted in significantly greater biofilm production (P < 0.0001). In addition, we tested an independently derived mutation in strain PAK and a Δ2794 PAK mutant. Although PAK did not produce significant amounts of biofilm under control conditions, and deletion of the 2794 locus had no apparent effect, overexpression of the cloned 2794 locus in Δ2794 PAK resulted in a significant increase in the production of biofilm compared with the PAK parental strain (P < 0.0001). Biofilm assays were then performed in a flow cell (Figure (Figure6C)6C) (24) and on a rotating disc reactor (Figure (Figure6D)6D) (25) in order to formally evaluate the ability of the bacteria to form structured communities. In each assay system, the biofilm produced by Δ2794 exhibited dramatically changed architecture, and complementation of the phenotype by the cloned gene was observed. To establish that the mutant Δ2794 exhibits similarly impaired biofilm formation on epithelial cells, we incubated GFP-expressing bacteria with monolayers of airway epithelial cells and observed by fluorescence imaging that the Δ2794 organisms did not cluster or autoagglutinate, in contrast to PAO1 (Figure (Figure6E). 6E).

Figure 6
Comparison of biofilm production by PAO1 and Δ2794.

Neuraminidase inhibitors block biofilm production.

Drugs that target the neuraminidase produced by influenza viruses are an important component of antiviral chemotherapy, used for both prophylaxis and treatment. As bacterial and viral neuraminidases can share common ASP boxes that interact with sialic acid (19), we postulated that the neuraminidase inhibitors designed to block the influenza enzyme (26) might have sufficient avidity for the active site of the bacterial neuraminidase to inhibit biofilm formation. We tested the effects of the influenza virus neuraminidase inhibitors oseltamivir (27) and peramivir (28) on PAO1 biofilm formation using the crystal violet assay (Figure (Figure7,7, A and B). A dose-dependent effect was observed with each of the 2 drugs, suggesting that P. aeruginosa biofilm formation may be a target to prevent infections in patients at risk by using neuraminidase inhibitors.

Figure 7
Dose-dependent inhibition of biofilm production in response to viral neuraminidase inhibitors.

To document that these viral neuraminidase inhibitors are specifically interacting with the bacterial neuraminidase, we also tested their effect in blocking neuraminidase activity using the fluorescent substrate 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (Figure (Figure7C).7C). The V. cholerae enzyme as well as the P. aeruginosa PAO1 enzyme were inhibited by peramivir, suggesting that the active sites of both types of neuraminidases have some affinity for the available viral neuraminidase inhibitor.


Bacterial neuraminidases have long been implicated in the pathogenesis of mucosal infection. Their prevalence and conservation among a very broad range of important human pathogens such as S. pneumoniae and V. cholerae as well as commensal flora, Mycoplasma (29), and even the gut flora of fish (30) implies a critical role in microbial ecology, which may vary according to bacterial species and sites of infection (1). The contribution of neuraminidase expression to the pathogenesis of respiratory infection is complex. The expected analyses of isogenic neuraminidase mutants has been accomplished in few bacterial species, due to gene redundancies (31, 32), involvement in metabolic pathways, and perhaps technical issues, as the construction of mutants has been unexpectedly difficult.

Initial studies of the P. aeruginosa neuraminidase performed with purified enzyme and in vitro analyses were entirely consistent with a role for the enzyme in modifying airway epithelial cell surfaces to facilitate bacterial attachment (6). Moreover, as CF airways were more readily modified than were normal airway cells (11), the Pseudomonas enzyme seemed likely to be important in that disease. However, in the studies presented herein, performed under more physiological conditions in vivo using isogenic mutants, we now find an entirely different function for the P. aeruginosa neuraminidase. The neuraminidase appears to be important for biofilm production, the cell-cell interactions which are critical even in the initial colonization process. Exactly how the PA2794 neuraminidase is involved in biofilm synthesis is unclear. Although the components of the PAO1 biofilm have not been fully defined, those of another P. aeruginosa, PA14, do not include sialic acid (33), indicating that the neuraminidase activity may be directed against a different sugar linkage on the bacterial surface. Pseudaminic acid — or a structure containing pseudaminic acid, a 9-carbon acidic sugar with structural similarity to the neuraminic acids — is a potential substrate and modifies several surface structures including LPS (34), pili (35), and flagella (36) in P. aeruginosa. Recent studies indicate that there are significant homologies among the genes involved in sialic acid O-acetylation in many bacterial species including P. aeruginosa strain 012, which produces pseudaminic acid but not sialic acid (37). Pseudaminic acid is involved in the glycosylation of Campylobacter pylori flagella (38), and mutants that lack pseudaminic acid fail to autoagglutinate (as we found in the Δ2794 mutant) and are attenuated in a ferret model of diarrheal disease. Mutations in the biosynthetic pathway involved in the addition of pseudaminic acid to flagella appear to contribute to this phenotype. Just as autolysins are necessary for cell wall biosynthesis, enzymes capable of cleaving carbohydrate linkages are necessary for the growth and modification of extracellular polysaccharides during biofilm biosynthesis (39).

A recent survey of virulence factors expressed by P. aeruginosa isolated from CF patients indicated that the PA2794 neuraminidase locus is one of the most highly conserved (14). This is consistent with its role in biofilm production, as the primary mode of P. aeruginosa growth in the CF lung is in biofilm (40, 41). However, in contrast to current paradigms regarding P. aeruginosa gene expression in the CF lung, our data implies that cell-cell communication, as manifested by biofilm production, is critical even in the initial colonization process. In vivo, both mucin (42) and the presence of neutrophils (43) contribute to biofilm formation. Although the presence of “mature” biofilms with complex secondary structures may be more typical of long-standing infection, our data suggest that neuraminidase production is involved in cell-cell interactions necessary for colonization and persistence in the airway. The involvement of the neuraminidase locus appears to contribute to the initial stages of biofilm development. The Δ2794 mutants trapped in a planktonic form of growth were fully virulent in a model of i.p. sepsis in which replication and induction of a host immune response are sufficient to cause mortality, but could not efficiently colonize the lung. Additional in vitro assays assessing immunostimulatory interactions with both macrophages and epithelial cells revealed no significant differences among the wild-type and mutant strains. The biologically significant consequence of the loss of neuraminidase appears to be limited to its defect in cell-cell aggregation.

The importance of biofilm production in the pathogenesis of respiratory tract infection caused by other common respiratory pathogens such as H. influenzae (21, 44) and S. pneumoniae has been well described (45). Less clear is whether these biofilms require the participation of neuraminidases for biosynthesis or modification. H. influenzae are known to produce sialylated biofilms that are important in the pathogenesis of mucosal infections, such as otitis media (46). While neuraminidase production by Hemophilus species has been reported (47), its specific involvement in colonization or pathogenesis has not yet been established. Several functions have been ascribed to the pneumococcal neuraminidase(s), which can desialylate host proteins (5) as well as surface components from adjacent flora (48) but does not appear to be critical for invasive infection (49), as was the case for the Pseudomonas enzyme. The surface location of the pneumococcal enzyme is consistent with a role in biofilm biology (4) but more definitive, functional experiments are necessary.

The mucosal surface of the gut is also colonized by organisms in biofilms (50), and neuraminidase expression has been well characterized in gastrointestinal pathogens (50) including Salmonellae (51), Vibrios (52), and Bacteroides (8). Neuraminidases contribute to bacterial metabolism in some of these organisms, and bacterial surface sialylation may provide an immune masking function as well (3). However, even though neuraminidase expression by V. cholerae has been characterized for 40 years (52), its specific contribution to the pathogenesis of cholera remains obscure (53). Although cholera toxin targets sialic acid, it has never been clearly established how the neuraminidase is linked to the toxin (53) or if the enzyme is also involved in cell-cell interactions and the colonization process. There may be technical issues that have limited the analysis of cloned genes that contribute to biofilm formation, as it has only recently been recognized that the TEM β-lactamase often used for selection interferes with biofilm formation (54).

There has been great interest in identifying bacterial gene products that are essential for pathogenesis, as these could be targeted in the patient populations known to be at high risk for infection. This is an especially appealing strategy to prevent P. aeruginosa infection in CF and intensive care patients. Viral neuraminidase inhibitors have been very useful in the prevention and treatment of influenza, targeting similar high-risk patient populations. The PA2794 neuraminidase shares many conserved elements and folds in the manner predicted for other microbial neuraminidases (19, 55). A preliminary analysis of PA2794 crystal structure indicates that the enzyme shares the same sialic acid binding fold as does the influenza enzyme, but otherwise has little homology (L. Tong and Y.-S. Hsiao, unpublished observations). The activity of the viral neuraminidase inhibitors in blocking P. aeruginosa biofilm production in vitro suggests that bacterial neuraminidases may also be a useful target to prevent infection in patients at high risk. These or similar compounds optimized for activity against bacterial enzymes could be especially useful in preventing P. aeruginosa colonization in CF patients. As neuraminidase expression is so highly conserved in mucosal pathogens, it should be possible to determine whether this approach blocks bacterial biofilm production and infection by other common pathogen.


Construction of a P. aeruginosa PAO1 neuraminidase null mutant

A nanA null mutant (Δ2794) was constructed by allelic replacement. An in-frame nonpolar deletion allele was constructed by removing the nanA coding sequence corresponding to amino acids 5–435 of the predicted 438-residue polypeptide and used to replace the full-length gene (1,317 base pairs) by the method previously described (56). Primers were designed using the published DNA sequence for the neuraminidase gene (designated PA2794) from P. aeruginosa strain PAO1 (GenBank accession no. AF236853). A nanA complementation plasmid was constructed by cloning a PCR product corresponding to the full-length neuraminidase open reading frame into plasmid pMMBGW with either a gentamicin or a penicillin resistance marker (56). The complementation clone or an empty vector control was introduced into the Δ2794 mutant by conjugation and selection on gentamicin (40 μg/ml) or piperacillin (100 μg/ml). The same procedure was carried out to generate a Δ2794 mutation in the P. aeruginosa strain PAK. The following primers were used for genotyping: internal to PA2794, 5′-CGCACTATACACAGGAACACG-3′ and 5′-GCCTAGCGGAAGGATCGTCGC-3′; external to PA2794, 5′-GATTATAAGTCTGCCGTCGG-3′ and 5′-CTCGGGAAACGTGCACATCC-3′.

Bacterial strains and culture conditions.

The standard laboratory strain of P. aeruginosa PAO1 was used as a prototype, grown in Luria broth (LB) or M9 media with Mg-glu as indicated. For complementation studies, the PA2794 locus was overexpressed in E. coli using pMMB67EH.gm and pMMB67EH.amp. Growth curves were obtained by growing bacteria in M9 media — with 40 μg/ml gentamicin or 100 μg/ml of piperacillin selection for strains containing plasmid — overnight to stationary phase, then diluting 1:1,000 in fresh media and incubating at 37°C with shaking and OD600 readings taken over time.

Epithelial cell culture.

Originally obtained from D. Gruenert (California Pacific Medical Center Research Institute, San Francisco, California, USA), 1HAEo and 16HBE cells were grown in minimum essential medium with Earle’s salts supplemented with 10% fetal calf serum (Molecular Probes) as previously described (57). RAW cells were grown in RPMI medium 1640 with 10% fetal calf serum.

Biofilm assays.

An overnight culture of bacteria grown in LB with shaking was diluted 1:100, and 100-μl aliquots added to 96-well microtiter plates were incubated for 24–48 hours at 37°C (58). Crystal violet (0.1%) was added to each well for 15 minutes, rinsed 3 times with water, and then released with the addition of 200 μl of 95% ethanol. Absorbance was determined at 540 nm. For experiments with inhibitors, the following modifications in the assay were used: for oseltamivir, an overnight culture of bacteria was diluted 1:100 in different doses of inhibitor in LB, and 100 μl aliquots were plated and assayed as described above; for peramivir, an overnight culture of bacteria was diluted 1:100 in different doses of inhibitor in LB, incubated at room temperature for 48 hours, and then diluted 1:2 in LB, and 100 μl aliquots were plated and assayed as described above. Each sample was tested in sextuplicate, the assay was repeated on 3 separate occasions, and representative data are shown. For the complementation studies, all of the PAO1 strains were transformed with either the control vector or the vector expressing the 2794 locus. Flow cell experiments and confocal microscopy were performed as previously described (24). For visualization by confocal microscopy, pMRP9-1 (which expresses GFP) was transformed into appropriate strains (59). The rotating disk reactor (25) was used for generating biofilms for microscopy and quantitative counts. Tryptic soy broth medium (1:100 strength) was used for these experiments.

Neuraminidase assays.

The PAO1 enzyme (10 μg/ml) was overexpressed and purified from E. coli using the pET28a vector (Novagen, EMD Biosciences), and a control V. cholera neuraminidase (0.1 U/ml; Calbiochem, EMD Biosciences) was incubated with the fluorescent substrate 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (Sigma-Aldrich) (25 μM in 0.9% NaCl) with or without peramivir (0.25 and 2.5 μM) for 24–48 hours, and fluorescence was read at excitation 360 nm and emission 465 nm. Each data point was performed in sextuplicate. A representative experiment is shown.

IL-8 assays.

Confluent monolayers of 1HAEo cells, weaned from serum overnight, were washed and stimulated with bacteria (1 × 108 CFU/ml) for 30 minutes. Fresh media plus gentamicin (100 μg/ml) was added and then removed for chemokine analysis after 3 hours. ELISA for IL-8 (R&D Systems) was performed as previously described (56). Each data point was performed in quintuplicate and standardized by protein. Each experiment was performed at least 3 times, and a representative study is shown.

Quantification of epithelial sialylation by flow cytometry.

16HBE cells were grown in 24-well plates to confluence and exposed to bacterial supernatant concentrated 30-fold for 3–5 hours followed by 3 PBS washes. Cells were stained with rabbit polyclonal Anti asialo GM1 antibody (Wako) followed by Alexa Fluor 488 donkey anti-rabbit IgG (Molecular Probes). Cells detached from the plastic using 0.02% EGTA in HBSS were then fixed with 1% paraformaldehyde and analyzed on a FACSCalibur using CellQuest software (version 3.3; BD).

RAW cell binding and phagocytosis as determined by flow cytometry.

RAW cells, a murine monocyte-macrophage cell line, were grown in 10-cm dishes and exposed to 1 × 108 bacteria for 30 minutes at 37°C. After 4 washes with PBS, 2 ml HBSS plus 0.02% EGTA was added, and cells were harvested. Cells were counted in a hemacytometer, and 1 × 106 cells were aliquoted per microfuge tube. PBS (1 ml) was added to each tube, and cells were pelleted at 400 g for 5 minutes. For extracellular binding determination, cells were incubated in 5% normal serum in PBS. For determination of total external and internalized bacteria, cells were incubated with Perm/Wash buffer (BD Biosciences — Pharmingen). In both cases, cells were then stained with rabbit anti-OMP antibody followed by Alexa Fluor 488 donkey anti-rabbit secondary and fixed with 1% paraformaldehyde and analyzed on a FACSCalibur using CellQuest software (version 3.3; BD).

Mouse models of infection.

Mouse protocol number AAAA1718 was approved by the Institutional Animal Care and Use Committee at Columbia University. Seven day old BALB/c mice were inoculated i.n. with 2 × 108 CFU of PAO1 or Δ2794 in 10 μl of PBS or i.p. with 5 × 105 CFU of PAO1 or Δ2794 and euthanized 16 hours later with pentobarbital. Pneumonia was defined as the recovery of more than 1,000 CFU per lung, and bacteremia was defined as the recovery of bacteria from the spleen. The inflammatory response in vivo was assayed by flow cytometry as previously described (60). Single-cell suspensions of the lung were screened for the percentage of PMNs in the total leukocyte population by double staining with PE-labeled anti-CD45 and FITC-labeled anti-Ly6G antibodies (BD Biosciences — Pharmingen). Irrelevant, isotype-matched antibodies were used as a control. Cells were gated on the basis of their forward and side scatter profiles and analyzed for the expression of both CD45 and Ly6G.


Paraffin lung sections from mice infected with PAO1 and Δ2794 were stained with H&E.

Real-time PCR.

Lungs from PAO1- and Δ2794-inoculated mice were obtained 16–18 hours after inoculation and stored in RNAlater (Qiagen). RNA was isolated using the Qiagen RNeasy Mini Kit. cDNA was made from 1 μg of RNA using the iScript cDNA Synthesis Kit (Bio-Rad). For quantitative real-time PCR, amplification was performed in a LightCycler using the DNA Master SYBR Green I kit (Roche Diagnostics). Primers used for KC amplification were 5′-CCGCGCCTATCGCCAATGAGCTGCGC-3′ and 5′-CTTGGGGACACCTTTTAGCATCTTTTGG-3′, and 35 cycles were run with denaturation at 95°C for 8 seconds, amplification at 56°C for 10 seconds, and extension at 72°C for 12 seconds. Actin was amplified on each individual sample and used as control for standardization. Primers used for actin amplification were 5′-GTGGGGCGCCCCAGGCACCA-3′ and 5′-CGGTTGGCCTTGGGGTTCAGGGGGG-3′, and 35 cycles were run with denaturation at 95°C for 8 seconds, amplification at 63°C for 10 seconds, and extension at 72°C for 12 seconds.

Adherence assay.

16HBE airway epithelial cells were stimulated with bacteria for 1 hour. After washing with PBS to remove unbound organisms, cells were stained with polyclonal anti-OMP followed by Alexa Fluor 488–conjugated anti-rabbit IgG (Molecular Probes). Fixed cells were analyzed by flow cytometry to quantitate the number of bacteria bound to the surface.


For biofilm, neuraminidase, and IL-8 assays, means and standard deviations were calculated, and statistical significance was determined using 2-tailed unpaired Student’s t test (biofilm assays) and 1-way analysis of variance with Bonferroni’s post test (neuraminidase and IL-8 assays). Tests of statistical significance were performed with GraphPad InStat (version 3.0; GraphPad Software).


This work was funded by NIH grant R01 DK39693. M.I. Gomez was supported by a Cystic Fibrosis Foundation postdoctoral fellowship. We thank George Drusano and James MeSharry for providing peramivir and Stephen Lory for his help in constructing the mutants.


Nonstandard abbreviations used: asialoGM1, Galβ1,2GalNAcβ1,4Galβ1,4Glcβ1,1Cer, asialoganglioside gangliotetraosylceramide; CF, cystic fibrosis; LB, Luria broth; OMP, outer membrane protein; PMN, polymorphonuclear leukocyte.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 116:2297–2305 (2006). doi:10.1172/JCI27920.


1. Vimr E.R., Kalivoda K.A., Deszo E.L., Steenbergen S.M. Diversity of microbial sialic acid metabolism. Microbiol. Mol. Biol. Rev. 2004;68:132–153. [PMC free article] [PubMed]
2. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994;3:1687–1696. [PMC free article] [PubMed]
3. Vimr E., Lichtensteiger C. To sialylate, or not to sialylate: that is the question. Trends Microbiol. 2002;10:254–257. [PubMed]
4. Camara M., Boulnois G.J., Andrew P.W., Mitchell T.J. A neuraminidase fromStreptococcus pneumoniae has the features of a surface protein. . Infect. Immun. 1994;62:3688–3695. [PMC free article] [PubMed]
5. King S.J., et al. Phase variable desialylation of host proteins that bind toStreptococcus pneumoniae in vivo and protect the airway. . Mol. Microbiol. 2004;54:159–171. [PubMed]
6. Cacalano G., Kays M., Saiman L., Prince A. Production of thePseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression. . J. Clin. Invest. 1992;89:1866–1874. [PMC free article] [PubMed]
7. Krivan H.C., Roberts D.D., Ginsburg V. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAcβ1-4Gal found in some glycolipids. Proc. Natl. Acad. Sci. U. S. A. 1988;85:6157–6161. [PMC free article] [PubMed]
8. Godoy V.G., Dallas M.M., Russo T.A., Malamy M.H. A role forBacteroides fragilis neuraminidase in bacterial growth in two model systems. . Infect. Immun. 1993;61:4415–4426. [PMC free article] [PubMed]
9. Bouchet V., et al. Host-derived sialic acid is incorporated intoHaemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. . Proc. Natl. Acad. Sci. U. S. A. 2003;100:8898–8903. [PMC free article] [PubMed]
10. Leprat R., Michel-Briand Y. Extracellular neuraminidase production by a strain ofPseudomonas aeruginosa isolated from cystic fibrosis. . Ann. Microbiol. 1980;131B:209–222. [PubMed]
11. Saiman L., Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. . J. Clin. Invest. 1993;92:1875–1880. [PMC free article] [PubMed]
12. Baltimore R.S., Christie C.D., Smith G.J. Immunohistopathologic localization ofPseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. . Am. Rev. Respir. Dis. 1989;140:1650–1661. [PubMed]
13. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004;23:146–158. [PubMed]
14. Lanotte P., et al. Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. . J. Med. Microbiol. 2004;53:73–81. [PubMed]
15. Knirel Yu A., et al. The structure of O-specific polysaccharides and serological classification ofPseudomonas aeruginosa (a review). . Acta Microbiol. Hung. 1988;35:3–24. [PubMed]
16. Rosenfeld J.A., Sarkar I.N., Planet P.J., Figurski D.H., DeSalle R. ORFcurator: molecular curation of genes and gene clusters in prokaryotic organisms. Bioinformatics. 2004;20:3462–3465. [PubMed]
17. Henderson I.R., Navarro-Garcia F., Desvaux M., Fernandez R.C., Ala’Aldeen D. Type V protein secretion pathway: the autotransporter story. Microbiol. Mol. Biol. Rev. 2004;68:692–744. [PMC free article] [PubMed]
18. Corfield A.P., Veh R.W., Wember M., Michalski J.C., Schauer R. The release of N-acetyl- and N-glycolloyl-neuraminic acid from soluble complex carbohydrates and erythrocytes by bacterial, viral and mammalian sialidases. Biochem. J. 1981;197:293–299. [PMC free article] [PubMed]
19. Roggentin P., et al. Conserved sequences in bacterial and viral sialidases. Glycoconj. J. 1989;6:349–353. [PubMed]
20. Tang H.B., et al. Contribution of specificPseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. . Infect. Immun. 1996;64:37–43. [PMC free article] [PubMed]
21. Swords W.E., et al. Sialylation of lipooligosaccharides promotes biofilm formation by nontypeableHaemophilus influenzae . . Infect. Immun. 2004;72:106–113. [PMC free article] [PubMed]
22. Ernst R.K., et al. Specific lipopolysaccharide found in cystic fibrosis airwayPseudomonas aeruginosa . . Science. 1999;286:1561–1565. [PubMed]
23. O’Toole G., Kaplan H.B., Kolter R. Biofilm formation as microbial development. Annu. Rev. Microbiol. 2000;54:49–79. [PubMed]
24. Boles B.R., Thoendel M., Singh P.K. Self-generated diversity produces “insurance effects” in biofilm communities. Proc. Natl. Acad. Sci. U. S. A. 2004;101:16630–16635. [PMC free article] [PubMed]
25. Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature. 2002;417:552–555. [PubMed]
26. Hayden F.G., et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Jama. 1999;282:1240–1246. [PubMed]
27. McKimm-Breschkin J., et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 2003;47:2264–2272. [PMC free article] [PubMed]
28. Sidwell R.W., Smee D.F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Investig. Drugs. 2002;11:859–869. [PubMed]
29. Sethi K.K., Muller H.E. Neuraminidase activity inMycoplasma gallisepticum . . Infect. Immun. 1972;5:260–262. [PMC free article] [PubMed]
30. Sugita H., Shinagawa Y., Okano R. Neuraminidase-producing ability of intestinal bacteria isolated from coastal fish. Lett. Appl. Microbiol. 2000;31:10–13. [PubMed]
31. Berry A.M., Lock R.A., Paton J.C. Cloning and characterization ofnanB , a secondStreptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinantEscherichia coli . . J. Bacteriol. 1996;178:4854–4860. [PMC free article] [PubMed]
32. Polissi A., et al. Large-scale identification of virulence genes from Streptococcus pneumoniae . . Infect. Immun. 1998;66:5620–5629. [PMC free article] [PubMed]
33. Wozniak D.J., et al. Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1Pseudomonas aeruginosa biofilms. . Proc. Natl. Acad. Sci. U. S. A. 2003;100:7907–7912. [PMC free article] [PubMed]
34. Rocchetta H.L., Burrows L.L., Lam J.S. Genetics of O-antigen biosynthesis inPseudomonas aeruginosa . . Microbiol. Mol. Biol. Rev. 1999;63:523–553. [PMC free article] [PubMed]
35. Comer J.E., Marshall M.A., Blanch V.J., Deal C.D., Castric P. Identification of thePseudomonas aeruginosa 1244 pilin glycosylation site. . Infect. Immun. 2002;70:2837–2845. [PMC free article] [PubMed]
36. Schirm M., et al. Structural and genetic characterization of glycosylation of type a flagellin inPseudomonas aeruginosa . . J. Bacteriol. 2004;186:2523–2531. [PMC free article] [PubMed]
37. Lewis A.L., Hensler M.E., Varki A., Nizet V. The group B streptococcal sialic acid O-acetyltransferase is encoded byneuD , a conserved component of bacterial sialic acid biosynthetic gene clusters. . J. Biol. Chem. 2006;281:11186–11192. [PubMed]
38. Schoenhofen I.C., et al. Functional characterization of dehydratase/aminotransferase pairs from Helicobacter and Campylobacter: enzymes distinguishing the pseudaminic acid and bacillosamine biosynthetic pathways. J. Biol. Chem. 2006;281:723–732. [PubMed]
39. Vuong C., et al. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. J. Biol. Chem. 2004;279:54881–54886. [PubMed]
40. Costerton J.W. Anaerobic biofilm infections in cystic fibrosis. Mol. Cell. 2002;10:699–700. [PubMed]
41. Singh P.K., et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407:762–764. [PubMed]
42. Landry R.M., An D., Hupp J.T., Singh P.K., Parsek M.R. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. . Mol. Microbiol. 2006;59:142–151. [PubMed]
43. Walker T.S., et al. EnhancedPseudomonas aeruginosa biofilm development mediated by human neutrophils. . Infect. Immun. 2005;73:3693–3701. [PMC free article] [PubMed]
44. Greiner L.L., et al. NontypeableHaemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans. . Infect. Immun. 2004;72:4249–4260. [PMC free article] [PubMed]
45. Donlan R.M., et al. Model system for growing and quantifyingStreptococcus pneumoniae biofilms in situ and in real time. . Appl. Environ. Microbiol. 2004;70:4980–4988. [PMC free article] [PubMed]
46. Jurcisek J., et al. Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeableHaemophilus influenzae in the chinchilla middle ear. . Infect. Immun. 2005;73:3210–3218. [PMC free article] [PubMed]
47. Moncla B.J., Braham P., Hillier S.L. Sialidase (neuraminidase) activity among gram-negative anaerobic and capnophilic bacteria. J. Clin. Microbiol. 1990;28:422–425. [PMC free article] [PubMed]
48. Shakhnovich E.A., King S.J., Weiser J.N. Neuraminidase expressed byStreptococcus pneumoniae desialylates the lipopolysaccharide ofNeisseria meningitidis and Haemophilus influenzae : a paradigm for interbacterial competition among pathogens of the human respiratory tract. . Infect. Immun. 2002;70:7161–7164. [PMC free article] [PubMed]
49. Tong H.H., Blue L.E., James M.A., DeMaria T.F. Evaluation of the virulence of aStreptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. . Infect. Immun. 2000;68:921–924. [PMC free article] [PubMed]
50. Probert H.M., Gibson G.R. Bacterial biofilms in the human gastrointestinal tract. Curr. Issues Intest. Microbiol. 2002;3:23–27. [PubMed]
51. Crennell S.J., et al. The structures ofSalmonella typhimurium LT2 neuraminidase and its complexes with three inhibitors at high resolution. . J. Mol. Biol. 1996;259:264–280. [PubMed]
52. Ada G.L., French E.L., Lind P.E. Purification and properties of neuraminidase fromVibrio cholerae . . J. Gen. Microbiol. 1961;24:409–425. [PubMed]
53. Moustafa I., et al. Sialic acid recognition byVibrio cholerae neuraminidase. . J. Biol. Chem. 2004;279:40819–40826. [PubMed]
54. Gallant C.V., et al. Common beta-lactamases inhibit bacterial biofilm formation. Mol. Microbiol. 2005;58:1012–1024. [PMC free article] [PubMed]
55. Rothe B., Roggentin P., Schauer R. The sialidase gene fromClostridium septicum : cloning, sequencing, expression in Escherichia coli and identification of conserved sequences in sialidases and other proteins. . Mol. Gen. Genet. 1991;226:190–197. [PubMed]
56. Wolfgang M.C., Lee V.T., Gilmore M.E., Lory S. Coordinate regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway. Dev. Cell. 2003;4:253–263. [PubMed]
57. Ratner A.J., et al. Cystic fibrosis pathogens activate Ca2+ -dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. . J. Biol. Chem. 2001;276:19267–19275. [PubMed]
58. O’Toole G.A., Gibbs K.A., Hager P.W., Phibbs P.V., Kolter R. The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development byPseudomonas aeruginosa. . J. Bacteriol. 2000;182:425–431. [PMC free article] [PubMed]
59. Davies D.G., et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–298. [PubMed]
60. Gomez M.I., et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. . Nat. Med. 2004;10:842–848.. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...